Dialysis industry news

Stories from the dialysis comunity across the globe.



Renal Denervation (RDN) Devices Market to Thrive Due to Surge in Hypertension - Medgadget.com (blog) PDF Print
Medical_Devices5

Renal denervation (RDN) is a minimally invasive procedure used to treat hypertension. Owing to the benefits of RDN devices over drug therapy, the market is projected to grow by leaps and bounds.

Europe Holds Dominant Position in Global RDN Devices Market

Geographically, the global RDN devices market is divided into four main regions: North America, Europe, Asia Pacific, and Rest of the World. With an 80% share in 2012, Europe dominated the worldwide market, followed by Asia Pacific. Europe is also the fastest growing regional renal denervation devices market and is estimated to retain its leading position till 2021. There has been a surge in research and development activities in the field of renal denervation in Europe and numerous devices have gained approval over the past few years. The U.K., France, Italy, and Germany are some of the key RDN devices markets in Europe.

Browse Full Article @ http://www.transparencymarketresearch.com/article/renal-denervation-devices-market.htm

North America, Asia Pacific Emerge as Strong Competitors

FDA approvals for renal denervation devices are projected to rise in the next couple of years, boosting the North America RDN devices market. The increasing incidence of cardiovascular diseases owing to poor lifestyle patterns is another factor that has led to the growing demand for renal denervation devices in the region. Asia Pacific also has a widening patient pool, fuelling the RDN devices market in the region.

Medtronic’s Simplicity Most Widely Used RDN Product

Product-wise, the key renal denervation devices are Boston Scientific’s V2 (Vessix Vascular), Medtronic’s Symplicity, St. Jude’s EnlighHTN, ReCor Medical’s Paradise, and Covidien’s OneShot. Presently, only these five devices have received an approval for CE mark certification. However, no RDN therapy has received approval from the U.S. FDA. In 2012, Medtronic’s Symplicity was the most widely used renal denervation device and held an 85.5% share of the overall market. ReCor Medical’s Paradise is the sole ultrasound denervation system that has a CE certification. Thanks to intense competition among these product manufacturers and the threat of new players, innovative technologies are projected to impact the RDN devices market.

Radiofrequency-based Renal Denervation Devices Hold Largest Share

There are various technologies used in RDN devices such as ultrasound, radiofrequency, micro-infusion, cryoablation, nano-particles, and radiation. Of these, radiofrequency-based renal denervation devices held the largest share of the overall market owing to their benefits of time efficiency, reproducibility, and safety. This segment is projected to continue its dominance over the RDN devices market through 2021. However, the segment is also forecast to face intense competition from other expanding renal denervation technologies.

RDN Devices Market Stimulated by Rising Incidence of Hypertension

The global renal denervation devices market is primarily driven by the growing incidence of uncontrolled hypertension (uHTN) and treatment resistant hypertension (trHTN). An RDN procedure is short and has a permanent effect on the condition of a patient. As a result, the demand for renal denervation devices has gained momentum. Apart from this, the market is also fuelled by the rapid development of renal denervation devices and rise in the global aging population.

Get Free Sample @ http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=400

Lack of Awareness among Patients Impeding RDN Market

On one hand, there is a shortage of clinical evidence to support the effect of renal denervation devices, which restricts the expansion of the global market. On the other hand, compared to drug-based therapy, there is scant awareness about renal denervation procedures using RDN devices. This, coupled with unstable reimbursement policies, is projected to hamper the growth of the renal denervation devices market.

Renal Denervation Devices Market to Register Outstanding Growth

The global RDN devices market is poised for immense growth till the end of the decade. According to a report by Transparency Market Research, in 2012, the market for renal denervation devices stood at a value of US$88.5 million and is projected to grow to US$1.9 billion by 2021. If this value holds true, the global market will register a CAGR of 41.2% between 2012 and 2021.

Some of the prominent names in the RDN devices market are Boston Scientific Corporation, St. Jude Medical, Kona Medical, Mercator Medsystems, CardioSonic, Medtronic Inc., and Covidien PLC.

Browse Full Global Renal Denervation Devices Market Report With Complete TOC @ http://www.transparencymarketresearch.com/renal-denervation-devices-market.html

About us:
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY – 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free 866-552-3453
Email:  This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Website: http://www.transparencymarketresearch.com/

...

 
Identifying Common Treatment Recommendations in Clear Cell Renal Cell Carcinoma - Cancer Therapy Advisor PDF Print

Cancer Therapy Advisor

Identifying Common Treatment Recommendations in Clear Cell Renal Cell Carcinoma
Cancer Therapy Advisor
Heterogeneity of decision criteria was observed in most clinical scenarios comparing treatment algorithms in the treatment of metastatic clear cell renal cell carcinoma (mccRCC), according to an article published online in the journal The Oncologist.

...

 
FMS, THC And UHS, Pushing Health Services Industry Downward - TheStreet.com PDF Print
Your browser is not supported. Please upgrade to one of the following browsers:

Google Chrome

Mozilla Firefox

Apple Safari

Microsoft Internet Explorer 9+

You may proceed to the site by clicking here, however some pages might not work correctly.

...

 
US Dialysis Catheters Market Sees Minimally Invasive Techniques as the Latest ... - Medgadget.com (blog) PDF Print

Dialysis Catheters Market in the US 2015-2019 is an industry research report available at ReportsnReports.com. The analysts forecast dialysis catheters market in the US to grow at a CAGR of 2.11% over the period 2015-2019.

Dialysis Catheters Market in the US 2015-2019 is a 62 page report that provides 20 Exhibits to support the market research. Browse the report at http://www.reportsnreports.com/reports/384531-dialysis-catheters-market-in-the-us-2015-2019.html.

Covered in this report

The Dialysis catheters market in the US is segmented into two based on product type: acute dialysis catheters and chronic dialysis catheters.

The report, Dialysis Catheters Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the landscape of the dialysis catheters market in the US and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

The report recognizes the following companies as the key players in Dialysis Catheters Market in the US 2015-2019: AngioDynamics Inc., Covidien plc, C.R. Bard Inc. and Medical Components Inc.

Purchase a Copy of Report Dialysis Catheters Market in the US 2015-2019 at http://www.reportsnreports.com/purchase.aspx?name=384531.

Other Prominent Vendors in the market are: Argon Medical Devices, Baxter International, Merit Medical Systems and Teleflex.

Market driver:Growing ESRD and CKD patient population

Market challenge:Presence of alternative devices

Market trend:Increase in use of minimally invasive techniques

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

List of Exhibits:

Exhibit 1: Market research methodology
Exhibit 2: Snapshot of dialysis catheters market in US
Exhibit 3: Dialysis catheters market in US 2014-2019 ($ million)
Exhibit 4: Optimistic and pessimistic data: dialysis catheters market in US 2014-2019
Exhibit 5: Comparison of various vascular access methods
Exhibit 6: Trends in vascular access methods for dialysis in US 2010-2014
Exhibit 7: Segmentation of dialysis catheters market in US by product
Exhibit 8: Comparison of acute and chronic dialysis catheters
Exhibit 9: Segmentation of dialysis catheters market in US by product 2014
Exhibit 10: Common HAIs in acute care settings
Exhibit 11: AngioDynamics: business segmentation by category of product
Exhibit 12: AngioDynamics: segmentation of revenue by category of product 2014
Exhibit 13: AngioDynamics: segmentation of revenue by geography 2014
Exhibit 14: Covidien: business segmentation 2013
Exhibit 15: Covidien: business segmentation by revenue 2012 and 2013 ($ million)
Exhibit 16: Covidien: geographical segmentation by revenue 2013
Exhibit 17: C. R. Bard: product segmentation by revenue 2013
Exhibit 18: C. R. Bard: product segmentation by revenue 2012 and 2013 ($ million)
Exhibit 19: C. R. Bard: geographical segmentation by revenue 2013
Exhibit 20: Medical Components: product segmentatio

About Us:

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

...

 
Fresenius Medical Care AG Co. Given Average Rating of Hold by Brokerages ... - Dakota Financial News PDF Print

Fresenius Medical Care AG & Co. (NYSE:FMS) has received a consensus recommendation of “Hold” from the eleven research firms that are currently covering the firm, Analyst Ratings Net reports. Six equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $41.10.

Fresenius Medical Care AG & Co. (NYSE:FMS) traded down 0.88% on Wednesday, hitting $41.56. 39,558 shares of the company traded hands. The stock has a market cap of $25.26 billion and a PE ratio of 24.04. The stock’s 50-day moving average is $42.54 and its 200 day moving average is $41.33. Fresenius Medical Care AG & Co. has a 12 month low of $32.40 and a 12 month high of $44.34.

Fresenius Medical Care AG & Co. (NYSE:FMS) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.40 earnings per share (EPS) for the quarter, missing the analysts’ consensus estimate of $0.42 by $0.02. During the same quarter in the prior year, the company posted $0.42 EPS. The business had revenue of $4.20 billion for the quarter, compared to the consensus estimate of $4.13 billion. Fresenius Medical Care AG & Co.’s revenue was up 15.0% compared to the same quarter last year. Equities research analysts expect that Fresenius Medical Care AG & Co. will post $1.76 earnings per share for the current fiscal year.

Several brokerages have recently weighed in on FMS. RBC Capital boosted their price objective on shares of Fresenius Medical Care AG & Co. from $35.00 to $40.00 and gave the stock a “sector perform” rating in a report on Friday, July 31st. Commerzbank AG cut shares of Fresenius Medical Care AG & Co. to a “hold” rating in a research report on Friday, May 29th.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) is a kidney dialysis company. The Company provides dialysis care services related to the dialysis treatment a patient receives with end-stage renal disease (ESRD), as well as other health care services. FMC AG & CO. KGAA also provides dialysis products for the treatment of ESRD, which includes manufacturing and distributing products, such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. The Company’s health care services, referred to as care coordination services, include pharmacy services, vascular, cardiovascular and endovascular specialty services, non-dialysis laboratory testing services, physician services, hospitalist and intensivist services, health plan services and urgent care services. The Company also offers a range of dialysis drugs.image

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

...

 
<< Start < Prev 41 42 43 44 45 46 47 48 49 50 Next > End >>

Page 41 of 4210
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.